Diabetic drug cuts kidney failure risk by a third

Canagliflozin also reduced the risk of major cardiovascular events by 20%

A glucose-lowering medication has been found to have striking benefits in reducing the risk of kidney failure in patients with type 2 diabetes, an Australian-led study has found.


And research leaders believe the renal benefits may be common to other drugs in the SGLT-2 inhibitor class.

Researchers from the George Institute for Global Health analysed data from 4400 patients with type 2 diabetes and chronic kidney disease to determine whether canagliflozin could improve both renal and cardiovascular outcomes.

They found that, compared with placebo,